American Society of Hematology

Study design. aaIPI, age-adjusted International Prognostic Index; ACVBP: doxorubicin (75 mg/m2 at day 1), prednisone (60 mg/m2, days 1-5), cyclophosphamide (1200 mg/m2 at day 1), vindesine (2 mg/m2 at days 1 and 5), and bleomycin (10 mg at days 1 and 5); ASCT, autologous stem cell transplantation; BEAM, carmustine (300 mg/m2 at day 6); etoposide (200 mg/m2 from days −6 to −3); cytarabine (200 mg/m2 every 12 hours from days −6 to −3); melphalan (140 mg/m2 at day −2); C, cycle; CHOP, cyclophosphamide (750 mg/m2 at day 1), doxorubicin (50 mg/m2 at day 1), vincristine (1.4 mg/m2; maximum, 2 mg at day 1), and prednisone (40 mg/m2, days 1-5); MTX, methotrexate. (See Figure 1 in the article by Le Gouill et al that begins on page 2307.)

Study design. aaIPI, age-adjusted International Prognostic Index; ACVBP: doxorubicin (75 mg/m² at day 1), prednisone (60 mg/m², days 1-5), cyclophosphamide (1200 mg/m² at day 1), vindesine (2 mg/m² at days 1 and 5), and bleomycin (10 mg at days 1 and 5); ASCT, autologous stem cell transplantation; BEAM, carmustine (300 mg/m² at day 6); etoposide (200 mg/m² from days −6 to −3); cytarabine (200 mg/m² every 12 hours from days −6 to −3); melphalan (140 mg/m² at day −2); C, cycle; CHOP, cyclophosphamide (750 mg/m² at day 1), doxorubicin (50 mg/m² at day 1), vincristine (1.4 mg/m²; maximum, 2 mg at day 1), and prednisone (40 mg/m², days 1-5); MTX, methotrexate. (See Figure 1 in the article by Le Gouill et al that begins on page 2307.)

This Feature Is Available To Subscribers Only